Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

ClinicalTrials.gov ID: NCT06087835

Public ClinicalTrials.gov record NCT06087835. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria

Study identification

NCT ID
NCT06087835
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,835 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 95 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 7, 2023 (Actual)
Primary completion
Feb 18, 2027 (Estimated)
Completion
Feb 18, 2027 (Estimated)
Last update posted
Oct 13, 2026

2023 – 2027

United States locations

U.S. sites
64
U.S. states
22
U.S. cities
58
Facility City State ZIP Site status
Research Site Huntsville Alabama 35805 —
Research Site Sun City West Arizona 85375 —
Research Site Bakersfield California 93309 —
Research Site Huntington Park California 90255 —
Research Site Los Alamitos California 90720 —
Research Site Los Angeles California 90010 —
Research Site Northridge California 91324 —
Research Site Oxnard California 93036 —
Research Site San Carlos California 94070 —
Research Site San Dimas California 91773 —
Research Site Tarzana California 91356 —
Research Site Victorville California 92392 —
Research Site Arvada Colorado 80002 —
Research Site Denver Colorado 80230 —
Research Site Boynton Beach Florida 33435 —
Research Site Hialeah Florida 33016 —
Research Site Hollywood Florida 33024 —
Research Site Jacksonville Florida 32204 —
Research Site Jensen Beach Florida 34957 —
Research Site Miami Florida 33126 —
Research Site Miami Florida 33165 —
Research Site Orlando Florida 32806 —
Research Site Fayetteville Georgia 30214 —
Research Site Champaign Illinois 61822 —
Research Site Chicago Illinois 60616 —
Research Site Hinsdale Illinois 60521 —
Research Site Island Lake Illinois 60042 —
Research Site Skokie Illinois 60077 —
Research Site Bowling Green Kentucky 42101 —
Research Site Shreveport Louisiana 71101 —
Research Site Silver Spring Maryland 20901 —
Research Site Flint Michigan 48504 —
Research Site Flint Michigan 48532 —
Research Site Troy Michigan 48098 —
Research Site City of Saint Peters Missouri 63376 —
Research Site Albany New York 12205 —
Research Site Middletown New York 10940 —
Research Site Orchard Park New York 14127 —
Research Site Greenville North Carolina 27834 —
Research Site Jacksonville North Carolina 28546 —
Research Site Kinston North Carolina 28504 —
Research Site New Bern North Carolina 28562 —
Research Site Statesville North Carolina 28625 —
Research Site Wilmington North Carolina 28401 —
Research Site Wilmington North Carolina 28412 —
Research Site Winston-Salem North Carolina 27103 —
Research Site Maumee Ohio 43537 —
Research Site Pottstown Pennsylvania 19464 —
Research Site East Providence Rhode Island 02915 —
Research Site Kingsport Tennessee 37660 —
Research Site Arlington Texas 76015 —
Research Site Austin Texas 78726 —
Research Site Houston Texas 77004 —
Research Site Houston Texas 77099 —
Research Site Pearland Texas 77584 —
Research Site San Antonio Texas 78204 —
Research Site San Antonio Texas 78207 —
Research Site San Antonio Texas 78212 —
Research Site Sugar Land Texas 77478 —
Research Site South Salt Lake Utah 84115 —
Research Site Alexandria Virginia 22311 —
Research Site Newport News Virginia 23606 —
Research Site Mukilteo Washington 98275 —
Research Site Spokane Washington 99204 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 232 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06087835, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2026 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06087835 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →